ArticleCancer discovery2021
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 71 citations in OpenAlex.
- Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.Nature communications · 2025Trial
- A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.Nature communications · 2024Trial
- Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent PediatricFrontiers in public health · 2022Trial
- Molecular profiling and personalized medicine within EURACAN in the SPECTA Arcagen study in comparison to the France Genomic Medicine 2025 Plan in the AURAGEN platform in peritoneal mesotheliomas.Translational oncology · 2026Article
- Consensus Guideline for the Management of Peritoneal Mesothelioma.Annals of surgical oncology · 2026Review
- Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma.Frontiers in oncology · 2026Article
- Case Report: Iparomlimab and Tuvonralimab-based therapy for epithelioid malignant peritoneal mesothelioma: a three-case series.Frontiers in oncology · 2026Article
- Navigating Fertility Preservation in Epithelioid Peritoneal Mesothelioma: A Case Study.The American journal of case reports · 2025Article
- Surgical and oncological outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma : A retrospective single center experience.Wiener klinische Wochenschrift · 2025Article
- Pembrolizumab as an effective treatment for diffuse malignant peritoneal mesothelioma with long‑term survival: A case report and literature review.Oncology letters · 2025Article
- Recent Advances in Mesothelioma Treatment: Immunotherapy, Advanced Cell Therapy, and Other Innovative Therapeutic Modalities.Cancers · 2025Review
- Epidemiology and clinical characteristics of mesothelioma in the Chinese population: a multicenter study.Therapeutic advances in medical oncology · 2025Article
- Biomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review).Oncology letters · 2024Review
- Article
- Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk.Annals of surgical oncology · 2024Article
- Fever of unknown origin associated with immune checkpoint inhibitors.Frontiers in immunology · 2024Review
- Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy.Frontiers in oncology · 2024Review
- Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature.Frontiers in oncology · 2024Article
- Computational immunogenomic approaches to predict response to cancer immunotherapies.Nature reviews. Clinical oncology · 2024Review
- Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299.JTO clinical and research reports · 2023Article
Corrections and comments
- Commented on by
Authors and funding
34 authors at 2 institutions in 1 country.
Funding
Abstract
Malignant peritoneal mesothelioma (MPeM) is a rare but aggressive malignancy with limited treatment options. VEGF inhibition enhances efficacy of immune-checkpoint inhibitors by reworking the immunosuppressive tumor milieu. Efficacy and safety of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade (AtezoBev) was assessed in 20 patients with advanced and unresectable MPeM with progression or intolerance to prior platinum-pemetrexed chemotherapy. The primary endpoint of confirmed objective response rate per RECISTv1.1 by independent radiology review was 40% [8/20; 95% confidence interval (CI), 19.1-64.0] with median response duration of 12.8 months. Six (75%) responses lasted for >10 months. Progression-free and overall survival at one year were 61% (95% CI, 35-80) and 85% (95% CI, 60-95), respectively. Responses occurred notwithstanding low tumor mutation burden and PD-L1 expression status. Baseline epithelial-mesenchymal transition gene expression correlated with therapeutic resistance/response (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.